<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PERCORTEN V- desoxycorticosterone pivalate injection, suspension </strong><br>Novartis Animal Health US, Inc.<br></p></div>
<h1>Percorten V</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">NAH/PER/VI/6 
		     
	06/13</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1><span class="Bold">CAUTION: </span></h1>
<p class="First">Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1><span class="Bold">DESCRIPTION: </span></h1>
<p class="First">The active ingredient in PERCORTEN-V is desoxycorticosterone pivalate (DOCP). It is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. The molecular weight is 414.58. It is designated chemically as 21 (2,2-dimethyl-1-oxopropoxy)-pregn-4-ene3,20-dione. The empirical formula is C<span class="Sub">26</span>H<span class="Sub">38</span>O<span class="Sub">4</span> and the structural formula is: </p>
<p><img alt="Desoxycorticosterone pivalate (DOCP) structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5e9f71f1-09d4-4313-ad66-5cfffe428ba8&amp;name=percorten-v-03.jpg"></p>
<p>PERCORTEN-V is a white aqueous suspension. Each ml contains 25mg desoxycorticosterone pivalate, 10.5mg methylcellulose, 3mg sodium carboxymethylcellulose, 1mg polysorbate 80 and 8mg sodium chloride with 0.002% thimerosal as preservative in water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY: </span></h1>
<p class="First">Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin that results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins which produce the physiologic effects seen after administration.</p>
<p>DOCP is a long-acting ester of desoxycorticosterone acetate (DOCA) which is recognized as having the same qualitative effects as the natural mineralocorticoid hormone aldosterone.</p>
<p>The most important effect of DOCP is to increase the rate of renal tubular absorption of sodium. This effect is seen most intensely in the thick portion of the ascending limb of the loop of Henle. It also increases sodium absorption in the proximal convoluted tubule but this effect is less important in <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>. Chloride follows the sodium out of the renal tubule.</p>
<p>Another important effect of DOCP is enhanced renal excretion of potassium. This effect is driven by the resorption of sodium that pulls potassium from the extracellular fluid into the renal tubules, thus promoting potassium excretion.</p>
<p>DOCP also acts to increase extracellular fluid volume. The enhanced retention of sodium, chloride and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, creates an osmotic gradient that promotes water absorption from the renal tubules. The extracellular fluid volume is supported. This expands the blood volume and improves the venous return to the heart and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. The expanded blood volume and increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> may result in elevated blood pressure. PERCORTEN-V prevents the life threatening hypotensive <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and pre-renal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> observed in animals suffering from hypoadrenocorticism. </p>
<p><span class="Bold">The effects of PERCORTEN-V on electrolytes and extracellular fluid volume are dependent on a functioning kidney. Animals suffering from <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, pre-renal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and inadequate tissue perfusion must be rehydrated with intravenous fluid (saline) therapy, before starting PERCORTEN-V therapy. Primary <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be ruled out before starting PERCORTEN-V therapy.</span></p>
<p>DOCP is an insoluble ester of desoxycorticosterone. The crystals are injected intramuscularly as a micro-crystalline depot where they slowly dissolve over time.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1><span class="Bold">INDICATION: </span></h1>
<p class="First">For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1><span class="Bold">WARNING: </span></h1>
<p class="First">Do not use this drug in pregnant dogs. Do not use in dogs suffering from congestive heart disease, severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Keep this and all drugs out of the reach of children. In case of human consumption, contact a physician or Poison Control Center immediately.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS: </span></h1>
<p class="First">Some patients are more sensitive to the actions of PERCORTEN-V and may exhibit side effects in an exaggerated degree. Some patients may show signs of <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span> or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. The dosage of PERCORTEN-V should be reduced in these patients. Concomitant use of PERCORTEN-V with potassium-sparing diuretics, such as spironolactone, may counter the effect of PERCORTEN-V because desoxycorticosterone pivalate and potassium-sparing diuretics exhibit opposing mechanisms of action.</p>
<p>Like other adrenocortical hormones, PERCORTEN-V may cause severe side effects if dosage is too high or prolonged. It may cause <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, increased blood volume, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and cardiac enlargement. Excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> may indicate <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> secondary to <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>. PERCORTEN-V should be used with caution in patients with congestive heart disease, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">ADVERSE REACTIONS</span><span class="Bold"> (in controlled clinical field studies)</span><span class="Bold">: </span>
</h1>
<p class="First">The following adverse reactions have been reported following the use of PERCORTEN-V: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, skin and coat changes, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on injection and <span class="product-label-link" type="condition" conceptid="4317273" conceptname="Injection site abscess">injection site abscess</span>. Some of these effects may resolve with adjustments in dose or interval of PERCORTEN-V or con-comitant glucocorticoid medication.</p>
<p><span class="Bold">Post-Approval Experience, Rev. 2011:</span></p>
<p>The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse events are reported to FDA-CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reporting frequency in dogs: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, facial/muzzle <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> has been reported following DOCP administration.  For a complete listing of adverse reactions for  desoxycorticosterone pivalate injectable suspension reported to CVM see: <span class="Underline">http://www.fda.gov/AnimalVeterinary</span>.</p>
<p>To report suspected adverse drug events, contact Novartis Animal Health at 1-800-637-0281 or the FDA at 1-888-FDA-VETS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">EFFICACY: </span></h1>
<p class="First">PERCORTEN-V given intramuscularly at the appropriate dose and interval, is effective in replacing the mineralocorticoid deficit in dogs suffering from <span class="Underline">primary</span> hypoadrenocorticism.</p>
<p>Results of two 75-day clinical studies in dogs with primary hypoadrenocorticism have demonstrated the clinical efficacy of PERCORTEN-V. Each dog received three doses of PERCORTEN-V (on days 0, 25 and 50).</p>
<p>The results are summarized below. </p>
<table>
<col width="37">
<col width="264">
<col width="148">
<col width="148">
<tbody class="Headless">
<tr class="First">
<td></td>
<td></td>
<td align="center"><span class="Bold">Clinical Study</span></td>
<td align="center">
<span class="Bold">           </span><span class="Bold">Number</span>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td align="right"><span class="Bold">01</span></td>
<td align="right">
<span class="Bold">          </span><span class="Bold">02</span>
</td>
</tr>
<tr>
<td class="Toprule" align="center"></td>
<td class="Toprule">Number of Dogs</td>
<td class="Toprule" align="center">49</td>
<td class="Toprule" align="center">18</td>
</tr>
<tr>
<td class="Toprule" align="center"></td>
<td class="Toprule">
<span class="Bold">Average Diagnostic Values: </span><span class="Bold"></span>
</td>
<td class="Toprule" align="center"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td align="center"></td>
<td>Serum Sodium (mEq/L)</td>
<td align="center">128.4</td>
<td align="center">130.72</td>
</tr>
<tr>
<td align="center"></td>
<td>Serum Potassium (mEq/L)</td>
<td align="center">7.28</td>
<td align="center">7.47</td>
</tr>
<tr>
<td align="center"></td>
<td>Sodium/Potassium Ratio</td>
<td align="center">18.09</td>
<td align="center">17.86</td>
</tr>
<tr>
<td align="center"></td>
<td>ACTH Stimulation Test: </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="center"></td>
<td>Cortisol Resting (µg/dl)</td>
<td align="center">0.28</td>
<td align="center">0.68</td>
</tr>
<tr>
<td align="center"></td>
<td>Cortisol Post Stimulation (µg/dl)</td>
<td align="center">0.27</td>
<td align="center">1.34</td>
</tr>
<tr>
<td class="Toprule" align="center"></td>
<td class="Toprule">
<span class="Bold">Average PERCORTEN-V Dose (mg/lb</span>): </td>
<td class="Toprule" align="right"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td align="center"></td>
<td>Day 0</td>
<td align="center">0.97</td>
<td align="center">0.99</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 25</td>
<td align="center">0.96</td>
<td align="center">0.99</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 50</td>
<td align="center">0.94</td>
<td align="center">0.97</td>
</tr>
<tr>
<td align="center"></td>
<td>Concomitant Glucocorticoid (Pred)</td>
<td align="center">47%</td>
<td align="center">39%</td>
</tr>
<tr>
<td align="center"></td>
<td><span class="Bold">Sodium/Potassium Ratios </span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="center"></td>
<td>Day 0</td>
<td align="center">25.18</td>
<td align="center">26.42</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 14</td>
<td align="center">36.36</td>
<td align="center">–</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 25</td>
<td align="center">29.64</td>
<td align="center">–</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 39</td>
<td align="center">34.94</td>
<td align="center">–</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 50</td>
<td align="center">30.33</td>
<td align="center">–</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 64</td>
<td align="center">35.30</td>
<td align="center">–</td>
</tr>
<tr>
<td align="center"></td>
<td>Day 75</td>
<td align="center">30.32</td>
<td align="center">30.59</td>
</tr>
<tr class="Last">
<td align="center"></td>
<td>% Efficacy Therapy</td>
<td align="center">96%</td>
<td align="center">100%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">Case Management:</span><span class="Bold"><span class="Sup">1,2</span></span><span class="Bold"> </span>
</h1>
<p class="First">An accurate diagnosis of primary canine adrenocortical insufficiency is of paramount importance for treatment success and should be established before initiation of PERCORTEN-V therapy. While <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are highly suggestive of adrenocortical insufficiency, they are not pathognomonic. A definitive diagnosis can only be made with an ACTH stimulation test. At diagnosis, classic cases of canine adrenocortical insufficiency may include clinical signs. Those signs are <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and collapse, serum sodium values less than 135 mEq/L, serum potassium greater than 6 mEq/L, sodium/potassium ratios below 25:1, plasma or serum cortisol concentration less than 4 µg/dl pre-and-post ACTH administration. Once the diagnosis is made, immediate therapy must be given to normalize <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, correct <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span> and re-establish normal homeostasis. Such therapy should include large volumes of intravenous physiologic saline, glucocorticoids (i.e., prednisolone, dexamethasone) at <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> doses and PERCORTEN-V. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (normocytic, normochromic) may be present at diagnosis, but not identified due to hemoconcentraton.  Rapid rehydration may reduce the circulating red blood cell count to life-threatening levels in animals with preexisting <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Once the acute crisis has passed, renal and cardiovascular function should return to normal.  Patient monitoring and dose adjustments of PERCORTEN-V and glucocorticoids should be instituted at this time (see Dosage).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">SAFETY:</span><span class="Bold"><span class="Sup">3</span></span><span class="Bold"> </span>
</h1>
<p class="First">In a laboratory study the safety of PERCORTEN-V was established in five month old Beagle dogs. PERCORTEN-V was administered IM to 24 Beagles at 0, 2.2, 6.6 or 11 mg/kg of body weight daily over a consecutive 3-day period every 28 days (equivalent to a cumulative monthly dosage of 0, 6.6,19.8 or 33 mg/kg) for 6 months. This resulted in no mortality or any significant effects on body weight, food consumption, and ophthalmic observations at any dose level. However, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> were noted and creatinine concentration decreased (14-89 mg/dl) in the 1X, 3X and 5X groups. Histopathological changes were only observed in the kidneys when PERCORTEN-V was administered at ≥ 6.6 mg/kg. The primary renal lesion consisted of glomerulonephropathy seen in all males at ≥ 6.6 mg/kg, in one female at 6.6 mg/kg, and in all females at 11 mg/kg. Other possible treatment related lesions in the kidney, observed sporadically in the 6.6 and 11.0 mg/kg groups, were tubular <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and tubular dilatation. Glomerulonephropathy may possibly be attributed to the pharmacological effects of the drug although there were no clinical measurements assessed in this study. In conclusion, PERCORTEN-V was well tolerated, when administered at 2.2 mg/kg on three consecutive days in every 28-day period for six months.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">DOSAGE:</span><span class="Bold"><span class="Sup">1,2</span></span><span class="Bold"> </span>
</h1>
<p class="First">In treating canine hypoadrenocorticism, PERCORTEN-V replaces the mineralocorticoid hormones only. Glucocorticoid replacement must be supplied by small daily doses of glucocorticoid hormones (e.g., prednisone or prednisolone) (0.2 - 0.4 mg/kg/day).</p>
<p>Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Begin treatment with PERCORTEN-V at a dose of 1.0 mg per pound of body weight every 25 days. In some patients the dose may be reduced. Serum sodium and potassium levels should be monitored to assure the animal is properly compensated. Most patients are well controlled with a dose range of 0.75 to 1.0 mg per pound of body weight, given every 21 to 30 days.</p>
<p>The well-controlled patient will have normal electrolytes at 14 days after administration or may exhibit slight <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. This needs no additional therapy as long as the patient is active and eating normally. Watch closely for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> which indicate a probable glucocorticoid deficiency.</p>
<p>At the end of the 25-day dosing interval, the patient should be clinically normal and have normal serum electrolytes. Alternatively, they may have <span class="Underline">slight</span> <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="Underline">slight</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. This constellation of signs indicate that the dosage and dosage interval should not be altered.</p>
<p>If the dog is not clinically normal or serum electrolytes are abnormal, then the dosage interval should be decreased 2-3 days.</p>
<p>Occasionally, dogs on PERCORTEN-V therapy may develop <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> (PU/PD). This usually indicates excess glucocorticoid, but may also indicate a PERCORTEN-V excess. It is prudent to begin by decreasing the glucocorticoid dose first. If the PU/PD persists, then decrease the dose of PERCORTEN-V without changing the interval between doses. </p>
<p><span class="Bold">Please note: Failure to administer glucocorticoids is the most common reason for treatment failure.</span> Signs of glucocorticoid deficiency include <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Such signs should be treated with high doses of injectable glucocorticoids (prednisolone or dexamethasone), followed by continued oral therapy 0.2 - 0.4 mg/kg/day. Oral supplementation with salt (NaCl) is not necessary with animals receiving PERCORTEN-V. </p>
<p><span class="Bold">Guide to Maintenance Therapy </span><br>Starting Dose: <br>
		     
	DOCP 1 mg/lb every 25 days <br>
		     
	Prednisone 0.2 - 0.4 mg/kg/day </p>
<p>Guides for Adjustment: <br>
		     
	Clinical Problem/Solution </p>
<p>
		     
	<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span>/<span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">Polydipsia</span> <br>
		     
	
		     
	
		     
	→ decrease prednisone dose first, <br>
		     
	
		     
	
		     
	→ then decrease DOCP dose,<br>
		     
	
		     
	
		     
	→ do not change DOCP interval </p>
<p>
		     
	<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>
		     
	
		     
	
		     
	→ increase prednisone dose </p>
<p>
		     
	<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span><br>
		     
	
		     
	
		     
	→ decrease DOCP interval 2-3 days </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">ADMINISTRATION: </span></h1>
<p class="First">Before injection, shake the vial thoroughly to mix the microcrystals with the suspension vehicle. PERCORTEN-V suspension is to be injected intramuscularly. Care should be used to prevent inadvertent intravenous injection, which may cause acute collapse and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. Such animals should receive immediate therapy for <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> with intravenous fluids and glucocorticoids.</p>
<p>Once vial is broached, product should be used within 4 months.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED: </span></h1>
<p class="First">Multiple-Dose Vials, 4 ml, each ml containing 25 mg desoxycorticosterone pivalate (DOCP), 10.5 mg methylcellulose, 3 mg sodium carboxymethylcellulose, 1 mg polysorbate 80, and 8 mg sodium chloride with 0.002% thimerosal added as preservative in water for injection. Packed one vial per carton.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15"></a><p></p>
<h1><span class="Bold">STORAGE: </span></h1>
<p class="First">Store at room temperature, preferably between 15 and 30°C (59 and 86°F). Protect from light. Protect from freezing.</p>
<p><span class="Bold">References: </span></p>
<p>1. <span class="Underline">Canine and Feline Endocrinology and Reproduction</span>. Second Edition (1996), E. C. Feldman and R. W. Nelson, W. B. Saunders Co., New York and Third Edition (2004) Saunders/Eisevier, USA </p>
<p>2. <span class="Underline">Textbook of Veterinary Internal Medicine</span>. </p>
<p>Fourth Edition, S. J. Ettinger and E. C. Feldman editors, W. B. Saunders Co., New York, 1995. </p>
<p>3. <span class="Underline">Toxicity of desoxycorticosterone pivalate given at high doses to clinically normal Beagles for six months</span>, E. Chow, W. R. Campbell, J. C. Turnier, R. C. Lynn and K. L. Pavkov, Am. J. Vet. Res. 54(11):1954-1961, 1993.</p>
<p>Manufactured for: 
		     
	Novartis Animal Health US, Inc. <br>Greensboro, NC 27408, USA </p>
<p>
		     
	</p>
<p>NADA # 141-029, Approved by FDA. <br>©2013 Novartis</p>
<p>PERCORTEN-V is a registered trademark of Novartis AG.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>
<span class="Bold">PRINCIPAL DISPLAY PANEL</span><br>
</h1>
<p class="First"><span class="Bold">Percorten</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - V</span><br><span class="Bold">(desoxycorticosterone pivalate)</span><br><span class="Bold">Injectable Suspension</span> <br><span class="Bold">25 mg/ml</span><span class="Bold"><br>NOVARTIS</span><span class="Bold"><br>ANIMAL HEALTH</span></p>
<p><img alt="Percorten® - V
(desoxycorticosterone pivalate)
Injectable Suspension 
25 mg/ml
NOVARTIS
ANIMAL HEALTH
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5e9f71f1-09d4-4313-ad66-5cfffe428ba8&amp;name=percorten-v-04.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PERCORTEN V 		
					</strong><br><span class="contentTableReg">desoxycorticosterone pivalatae injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58198-5667</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DESOXYCORTICOSTERONE PIVALATE</strong> (DESOXYCORTONE) </td>
<td class="formItem">DESOXYCORTICOSTERONE PIVALATE</td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58198-5667-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141029</td>
<td class="formItem">01/12/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novartis Animal Health US, Inc.
							(966985624)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f7f634d1-5c48-46f9-9169-4ae37103360c</div>
<div>Set id: 5e9f71f1-09d4-4313-ad66-5cfffe428ba8</div>
<div>Version: 9</div>
<div>Effective Time: 20130801</div>
</div>
</div> <div class="DistributorName">Novartis Animal Health US, Inc.</div></p>
</body></html>
